论文部分内容阅读
目的本文就紫杉醇联合卡铂治疗卵巢癌的临床效果进行研究及探讨。方法将84例卵巢癌患者随机分为实验组(n=42)与参照组(n=42),参照组患者予以卡铂进行化疗,实验组予以紫杉醇联合卡铂进行化疗,对比两组患者的治疗总有效及不良反应。结果实验组患者的治疗总有效率显著高于参照组(P<0.05),两组患者的不良反应发生率比较无明显差异(P>0.05)。结论应用紫杉醇联合卡铂治疗卵巢癌可获得理想效果,且不会增加不良反应,具有较高的临床应用价值。
Objective To study the clinical effect of paclitaxel combined with carboplatin in the treatment of ovarian cancer. Methods 84 patients with ovarian cancer were randomly divided into experimental group (n = 42) and reference group (n = 42). Patients in the reference group received chemotherapy with carboplatin. The patients in the experimental group were treated with paclitaxel plus carboplatin. The total effective and adverse reactions. Results The total effective rate of the experimental group was significantly higher than that of the reference group (P <0.05). There was no significant difference between the two groups in the incidence of adverse reactions (P> 0.05). Conclusion Paclitaxel combined with carboplatin in the treatment of ovarian cancer can achieve the desired effect, and does not increase the adverse reactions, has a high clinical value.